Survodutide 10MG

Survodutide 10MG | GLP-1 and Glucagon Receptor Co-Agonist

A next-generation co-agonist studied for its dual-action impact on satiety and hepatic energy expenditure.

Survodutide is a synthetic peptide that acts as a dual agonist of the Glucagon-Like Peptide-1 (GLP-1) and Glucagon receptors. In advanced research, Survodutide is investigated for its potential to provide superior results in lipid reduction and weight loss compared to single GLP-1 agonists. By activating the glucagon receptor, it is researched for its ability to increase energy expenditure and directly impact liver health.

Research Benchmarks: Synergistic Metabolism

• Hepatic Lipid Management: Studying the reduction of liver fat in MASH/MASLD research models.
• Satiety Signaling: Investigating the GLP-1 mediated inhibition of appetite centers.
• BMR Elevation: Researching the glucagon-induced increase in basal metabolic rate.

Scientific Reference Library

• 🧪 Research: Pharmacological profile of the dual agonist Survodutide
• 🧪 Research: Impact of Survodutide on liver fat and fibrosis
• 🧪 Research: Mechanisms of weight loss via dual-receptor targeting